Prescription drug rebates on the rise
Prescription Spend

Tina Reed

Axios

May 9, 2022

Prescription drug rebates from drugmakers to commercial health plans are steadily increasing, a study published in JAMA Health Forum shows.

Why it matters: This is all part of a system in which drugmakers negotiate to get their product on the formularies of middlemen known as pharmacy benefit managers and health plans.

“While drug rebates can reduce plans’ net costs, rebates do not reduce patients’ cost sharing,” the authors write.

This can ultimately “incentivize drug manufacturers to inflate list prices and PBMs to distort drug formularies to favor high list price and high-rebate therapies,” the authors write.

What they’re saying: This is also an equity issue, particularly for patients buying individual plans.

“We have the sick people paying more than their fair share for the drug and the rebate goes back to the plan to reduce premiums for the healthy,” said Ge Bai, a professor of accounting at Johns Hopkins Carey Business School who was one of the authors of the study.

What to watch: Trump era rules to block rebates for Medicare stalled under the Biden administration.

But the issue has been gaining attention on Capitol Hill, with a bipartisan group of lawmakers pushing to outlaw rebates as part of legislation that would cap the price of insulin, FierceHealthcare wrote.

Continue Reading

The Watko Way – Innovative

The Watko Way – Innovative

Katie Mercurio, Account Manager May 5, 2022 I have worked at Watko since 2015. One thing I have learned over the last 7 years is that every client is unique, and therefore so is every solution. The Watko Way is meeting our customers where they are...

Specialty Drug Assistance Programs

Specialty Drug Assistance Programs

By Kari Hoback, Senior Account Manager April 21, 2022 Many employers are concerned with the increasing cost of prescription drugs, and in particular the high cost of specialty drugs.  In recent years, most plans have added a separate employee...